

REMARKS

The paper is in response to the Office Action mailed April 4, 2011 ("the Office Action"). Claim 28 has been amended.

Examiner's Interview

Applicant was not party to the Examiner Interview identified in the Office Action.

Rejection Under 35 U.S.C. §112,

The Office Action rejects claim 28 and 39-55 under 35 U.S.C. §112, first paragraph, and second paragraph as a written description rejection. Particularly, the Office Action has rejected the terminology "downstream." While Applicant respectfully disagrees with this allegation, Applicant has elected to amend the claim in order to further prosecution and allowance of the patent application. In response, Applicants have amended claim 28 to recite, "administering to the blood vessel or vascular malformation ~~at or downstream from the blocked blood flow~~ a composition comprising a nucleophilic component including pentaerythritol-tetrakis(3-mercaptopropionate) (QT) and a component containing a conjugated unsaturated bond including poly(propylene glycol)diacrylate," which shows the current amendment in mark-up. As such, the offending language has been removed. In view thereof, Applicant respectfully submits that the claims are now allowable.

CONCLUSION

In view of the foregoing, Applicants submit that the pending claims are allowable. In the event that Examiner finds remaining impediment to a prompt allowance of this application that may be clarified through a telephone interview or overcome by an Examiner's Amendment, Examiner is requested to contact the undersigned attorney.

Dated this 3rd day of May, 2011.

Respectfully submitted,

/Jonathan M. Benns, Reg. #53983/

JONATHAN M. BENNS

Registration No. 53,983

Attorney for Applicant

Customer No. 97149

Telephone No. (435) 252-1360